Abstract: A self-encrypting drive (SED) comprises an SED controller and a nonvolatile storage medium (NVSM) responsive to the SED controller. The SED controller enables the SED to perform operations comprising: (a) receiving an encrypted media encryption key (eMEK) for a client; (b) decrypting the eMEK into an unencrypted media encryption key (MEK); (c) receiving a write request from the client, wherein the write request includes data to be stored and a key tag value associated with the MEK; (d) using the key tag value to select the MEK for the write request; (e) using the MEK for the write request to encrypt the data from the client; and (f) storing the encrypted data in a region of the NVSM allocated to the client. Other embodiments are described and claimed.

Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.

Abstract: In one aspect the invention is arranged to provide a hair treatment apparatus adapted to reduce the temperature of hair. This apparatus includes at least one thermal energy storage core arranged to draw heat out of hair wherein said at least one thermal energy storage core is arranged to cool hair to a temperature below 0° Celsius.

Abstract: Systems, methods, and computer-readable storage devices are disclosed for improved concurrency of users of a shared virtual environment.

Abstract: Disclosed herein is a high-effective-concentration cannabinoid-based vape oil that is flowable within a vape device. The high-effective-concentration cannabinoid-based vape oil comprises a cannabinoid-based incipient and a cannabinoid-based target component. The cannabinoid-based incipient has an in-situ concentration that is less than the saturation concentration of the cannabinoid-based incipient. The cannabinoid-based target component has an in-situ concentration that is less than the saturation concentration of the cannabinoid-based target component. The in-situ concentration of the cannabinoid-based incipient and the in-situ concentration of the cannabinoid-based target component, taken together, is greater than the saturation concentration of the cannabinoid-based target component. The cannabinoid-based target component has an in-actio concentration that is greater than the saturation concentration of the cannabinoid-based target component.

Abstract: Systems and methods are for executing, by a data processing system, a workflow to process results data indicating an output of a data quality test on data records by generating, responsive to receiving the results data and metadata describing the results data, a data quality issue associated with a state and one or more processing steps of the workflow to resolve a data quality error associated with the data quality test. Operations include generating a workflow for processing results data based a state specified by a data quality issue. Generating the workflow includes: assigning, based on the results data and the state of the data quality issue, an entity responsible for resolving the data quality error; determining, based on the metadata, one or more actions for satisfying the data quality condition specified in the data quality test; and updating the state associated with the data quality issue.

Abstract: Some fluid coupling devices described herein are configured for use in fluid systems for purposes of providing a sterile connection for drug delivery. In some embodiments, the fluid coupling devices can be implemented as multi-use, sterile fluid coupling devices that are configured to reduce the likelihood of fluid spillage when being disconnected.

Abstract: The present invention relates to a substrate having (a) a first material applied to at least a portion of the substrate, and (b) a coating layer deposited from a liquid coating composition including a film-forming resin, and optionally a crosslinker that is reactive with the film-forming resin, in direct contact with at least a portion of the substrate to which the first material has been applied. The first material is (i) a catalyst that catalyzes cure of the liquid coating composition, (ii) a component reactive with the film-forming resin and/or the crosslinker of the liquid coating composition, and/or (iii) a rheology modifier.

Abstract: The present invention relates to a substrate having (a) a first material applied to at least a portion of the substrate, and (b) a coating layer deposited from a powder coating composition including a film-forming resin, and optionally a crosslinker that is reactive with the film-forming resin, in direct contact with at least a portion of the substrate to which the first material has been applied. The first material is (i) a catalyst that catalyzes cure of the powder coating composition, (ii) a component reactive with the film-forming resin and/or the crosslinker of the powder coating composition, and/or (iii) a rheology modifier.

Abstract: The disclosed invention is a compact, folding, expandable, wall-mount massage device. The device has two primary configurations: the first is a long, collapsed shape for storage and travel; the second is a shorter, wider, expanded shape for use. The primary components of the device are: a massage element, shown as a sphere in the drawings; and a frame, the frame supporting the massage element during use. The frame includes a central column, surrounded by one or more folding support legs/stabilizing legs. In the collapsed position the folding legs lay near or against the central column, thus reducing the size of the device. In an in-use, or expanded position, the collapsing leg supports move outward, resting against the base of the central column. The result is a wide base that protrudes from the central column in multiple directions.

Abstract: In one aspect the invention provides a boat support frame loading and unloading apparatus configured to draw a boat on to and off a boat support frame. This boat support frame has a loading end and a terminal end opposite to the loading end. The apparatus provided includes at least one roller assembly mounted to the support frame adjacent to the loading end of the support frame, said at least one roller assembly incorporating at least one roller element. The apparatus also includes at least one drive mechanism configured to rotate one or more roller elements to draw a boat onto and off the support frame through the loading end of the support frame. The roller assembly also includes a hull contact surface formed by a flexible belt which has a circumference greater than the circumference of the said at least one roller element incorporated into the roller assembly.

Abstract: Systems, methods, and computer-readable storage devices are disclosed for improved concurrency of users of a shared virtual environment.

Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.